Abstract: The present invention relates to a method, oligonucleotides, reaction mixtures and kits for the selective amplification of a messenger RNA target comprising an exon-exon junction, using an oligonucleotide that comprises at least one nucleotide modified at the exocyclic amino group.

Abstract: The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting, patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor.

Abstract: The present invention provides methods of extending primer nucleic acids and sequencing target nucleic acids. The methods include the use of 2?-terminator nucleotides to effect chain termination. In addition to related reaction mixtures and kits, the invention also provides computers and computer readable media.

Abstract: A watercraft in the form of a body board comprising a planar body and a display unit adapted to display at least one animated image. The image is disposed at a bottom side of a lenticular lens. Each of the frames comprise an image of a head of a shark having a mouth opened at a predetermined width, thereby forming an animated image of the shark moving mouth so as to repel sharks. The display unit comprises a digital display, a controller and a power supply unit wherein the controller comprises memory for storing images and controls the images for displaying on the digital screen. The digital display comprises LCD. The supply unit comprises a solar power panel disposed on the top surface of the watercraft.

Abstract: The present invention provides methods of extending primer nucleic acids and sequencing target nucleic acids. The methods include the use of 2?-terminator nucleotides to effect chain termination. In addition to related reaction mixtures and kits, the invention also provides computers and computer readable media.

Abstract: The present invention provides methods of extending nucleic acids and purifying target nucleic acids. The methods include the use of capping reagents to effect chain termination and provide a handle for purification via fluorous affinity methods.

Abstract: A system and method are provided for estimating NOx produced by an internal combustion engine. The flow rate of fuel supplied to the engine and a plurality of engine operating parameters are monitored. NOx produced by the engine is estimated based on a product of the flow rate of fuel and a function of the plurality of engine operating parameters. The NOx estimate is stored in memory.

Abstract: The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor

Abstract: The present invention provides methods of extending primer nucleic acids and sequencing target nucleic acids. The methods include the use of 2?-terminator nucleotides to effect chain termination. In addition to related reaction mixtures and kits, the invention also provides computers and computer readable media.

Abstract: The present invention provides methods of extending primer nucleic acids and sequencing target nucleic acids. The methods include the use of 2?-terminator nucleotides to effect chain termination. In addition to related reaction mixtures and kits, the invention also provides computers and computer readable media.

Abstract: A system and method are provided for estimating NOx produced by an internal combustion engine. The flow rate of fuel supplied to the engine and a plurality of engine operating parameters are monitored. NOx produced by the engine is estimated based on a product of the flow rate of fuel and a function of the plurality of engine operating parameters. The NOx estimate is stored in memory.

Abstract: There is disclosed a method for glycemic control of a patient having a disease selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, and postprandial hyperglycemia, said method comprising administering to a patient in need thereof a pharmaceutical composition comprising an acetyl cholinesterase inhibitor compound. There is further disclosed a method for reducing HbA1C concentrations as a measure of glycemic control, comprising administering to a patient in need thereof a pharmaceutical composition comprising an acetyl cholinesterase inhibitor compound. Lastly, there is disclosed a pharmaceutical formulation for daily administration comprising an acetyl cholinesterase inhibitor, from about 5 mg to about 15 mg of loratadine and optionally from about 5 mg to about 16 mg of elemental zinc.

Abstract: The present invention provides methods of extending nucleic acids and purifying target nucleic acids. The methods include the use of capping reagents to effect chain termination and provide a handle for purification via fluorous affinity methods.

Abstract: The invention provides methods of producing blocked oligonucleotides that include 2?-terminator nucleotides. These blocked oligonucleotides are used primers and probes in a variety of nucleic acid technologies. Related kits are also provided.

Abstract: The invention relates to detectable labels useful for detection of nucleotide sequences. Specifically, the invention relates to labeled-imidazole-PEG compounds, such as nucleosides, nucleotides, and nucleic acids incorporating such compounds, and methods utilizing such compounds. The invention further relates to kits comprising labeled imidazole-PEG compounds.

Abstract: The invention relates to detectable labels useful for detection of nucleotide sequences. Specifically, the invention relates to labeled-imidazole-PEG compounds, such as nucleosides, nucleotides, and nucleic acids incorporating such compounds, and methods utilizing such compounds. The invention further relates to kits comprising labeled imidazole-PEG compounds.

Abstract: This invention provides compositions and methods for HCV typing, e.g., genotyping and/or subtyping. The compositions and methods of the invention can be used to assign an HCV isolate to one of at least five HCV types (for example, selected from types 1, 2, 3, 4, 5 or 6), or to one of at least five subtypes (for example, subtypes 1a/b/c, 2a/c, 2b, 3a, 4a, 5a or 6a). These methods integrate the hybridization data from a plurality of HCV typing probes in a multidimensional analysis to make an HCV type assignment for an HCV in an experimental sample. The invention also provides related compositions, including, for example, the HCV typing probes and HCV typing diagnostic kits.

Abstract: The present invention relates generally to the transfer of non-fluorescent energy between donor and acceptor moieties. In certain embodiments, the invention provides biomolecules that include substantially non-fluorescent donor moieties. Processes involving these donor moieties typically entail reduced background fluorescence relative to applications that involve conventional fluorescent donor moieties. In addition to reaction mixtures and methods that include the use of these biomolecules, the invention also provides related kits and systems.

Abstract: The present invention provides methods, compositions, and kits for quantification and identification of target nucleic acid sequences, either in pure solutions or from mixtures of various nucleic acids. In other aspects, the invention provides compositions and methods for HCV genotyping.

Abstract: The present invention provides methods and probe nucleic acids for detecting mutant forms of target nucleic acids that comprise repetitive nucleotide sequences. In certain embodiments, for example, these approaches and reagents can be used to detect instability in regions of genomic DNA that include microsatellite markers. The invention also provides related reaction mixtures, systems, and kits.